New HIV prevention shot could last 4 months
NCT ID NCT06741397
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new version of the HIV prevention drug cabotegravir given as a shot every 4 months. About 229 teens and adults at risk for HIV will receive the injection to see how well the drug stays in the body and if it is safe. The goal is to make HIV prevention easier by reducing how often shots are needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Birmingham, Alabama, 35222, United States
-
GSK Investigational Site
Los Angeles, California, 90027, United States
-
GSK Investigational Site
Los Angeles, California, 90035, United States
-
GSK Investigational Site
Los Angeles, California, 90036, United States
-
GSK Investigational Site
Los Angeles, California, 90069, United States
-
GSK Investigational Site
Palm Springs, California, 92262, United States
-
GSK Investigational Site
Doral, Florida, 33172, United States
-
GSK Investigational Site
Ft. Pierce, Florida, 34982, United States
-
GSK Investigational Site
Orlando, Florida, 32803, United States
-
GSK Investigational Site
West Palm Beach, Florida, 33407, United States
-
GSK Investigational Site
Chicago, Illinois, 60612-7230, United States
-
GSK Investigational Site
New Orleans, Louisiana, 70112, United States
-
GSK Investigational Site
Springfield, Massachusetts, 01105, United States
-
GSK Investigational Site
Berkley, Michigan, 48072, United States
-
GSK Investigational Site
Kansas City, Missouri, 64111, United States
-
GSK Investigational Site
Las Vegas, Nevada, 89119, United States
-
GSK Investigational Site
New York, New York, 10029, United States
-
GSK Investigational Site
Valhalla, New York, 10595, United States
-
GSK Investigational Site
Greensboro, North Carolina, 27401-1209, United States
-
GSK Investigational Site
Cincinnati, Ohio, 45267, United States
-
GSK Investigational Site
Columbus, Ohio, 43210, United States
-
GSK Investigational Site
Pittsburgh, Pennsylvania, 15212, United States
-
GSK Investigational Site
Dallas, Texas, 75246, United States
-
GSK Investigational Site
Fort Worth, Texas, 76104, United States
-
GSK Investigational Site
Seattle, Washington, 98104, United States
-
GSK Investigational Site
San Juan, 00909, Puerto Rico
-
GSK Investigational Site
San Juan, 909, Puerto Rico